文献速递冠心病

冠状动脉疾病个体化抗血小板治疗:未来展望

Personalised antiplatelet therapies for coronary artery disease: what the future holds.
PubMed 文献 · Eur Heart J · 2023-01-01

该综述概述了冠状动脉疾病(CAD)个体化抗血小板治疗的现状与未来趋势,重点讨论急性冠脉综合征(ACS)及经皮冠状动脉血运重建患者。个体化策略通过平衡缺血与出血风险,借助临床、造影、实验室及床旁血小板功能检测和快速基因分型来优化治疗。

要点

  • 个体化抗血小板治疗旨在平衡血栓与出血风险。
  • 风险分层需整合临床、造影、实验室及血小板功能/基因检测。
  • 重点人群为ACS及接受经皮冠状动脉介入治疗的患者。

核心结论

  • 个体化抗血小板治疗通过定制治疗至患者个体需求和风险特征,优化安全性与疗效的平衡。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 对出血不良预后的认识加深,为定义既能减轻出血风险又不牺牲抗血栓保护策略奠定基础。
  • 风险分层传统上包括临床和人口学特征,已扩展至纳入造影特征和实验室发现。
  • 床旁血小板功能检测和快速基因分型检测可实现更个体化的抗血小板治疗选择。

临床怎么用

  • 临床医生应综合评估出血与血栓风险以选择最佳抗血小板治疗。
  • 可考虑使用床旁血小板功能检测和快速基因分型辅助个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary artery disease (CAD) is one of the leading causes of death globally, and antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as aspirin and P2Y12 inhibitors are commonly used to reduce the risk of thrombotic events, including myocardial infarction, stroke, and stent thrombosis. However, the benefits associated with the use of antiplatelet drugs also come with a risk of bleeding complications. The ever-growing understanding of the poor prognostic implications associated with bleeding has set the foundations for defining strategies that can mitigate such safety concern without any trade-off in antithrombotic protection. To this extent, personalised antiplatelet therapy has emerged as a paradigm that optimizes the balance between safety and efficacy by customizing treatment to the individual patient's needs and risk profile. Accurate risk stratification for both bleeding and thrombosis can aid in selecting the optimal antiplatelet therapy and prevent serious and life-threatening outcomes. Risk stratification has traditionally included clinical and demographic characteristics and has expanded to incorporate angiographic features and laboratory findings. The availability of bedside platelet function testing as well as rapid genotyping assays has also allowed for a more individualized selection of antiplatelet therapy. This review provides a comprehensive overview of the current state of the art and future trends in personalised antiplatelet therapy for patients with CAD, with emphasis on those presenting with an acute coronary syndrome and undergoing percutaneous coronary revascularization. The aim is to provide clinicians with a comprehensive understanding of personalised antiplatelet therapy and facilitate informed clinical decision-making.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Capodanno, Angiolillo. Personalised antiplatelet therapies for coronary artery disease: what the future holds. Eur Heart J. 2023. PMID: 37345589. doi:10.1093/eurheartj/ehad362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。